Ying Huang Recent News
Strong Trial Results, Effective Distribution Could Put Regeneron's Praluent 'Back In The Competition'
With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline
BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A
BioMarin Pharma Crashed This Week, So Why Is This Mega-Bank Still Bullish?
The Historical Correlation Between Biotech Stocks And Interest Rates
Gilead Sciences: Here's What A Bull And A Bear Are Saying
Intercept Pharmaceuticals Downgraded
Top Street Analysts Like Gilead Sciences
Biogen Investors: Active Ingredient In Patient Death Is Not Changing BofA's Forecast
Bank Of America Believes Shares Of Amgen Are Fairly Valued
Bank Of America Downgrades Gilead Sciences, Sees Possible Pricing War
UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts
Bank Of America Is Impressed By Takeaways From Vertex Pharmaceuticals Conference Call
UPDATE: Barclays Initiates Coverage on GlycoMimetics
UPDATE: Barclays Downgrades Ariad Pharmaceuticals Following News of Iclusig Clinical Hold